CStone Pharmaceuticals

Market position

CStone is described as one of China's innovative pharmaceutical companies with a position in immuno-oncology; its 2018 Series B was characterized as the largest Series B financing in the history of the China biopharmaceutical industry. Comparable companies listed by a third-party data provider include Legend Biotech, Zai Lab, Innovent Biologics, Ascentage Pharma, CARsgen Therapeutics, Adagene and Fosun Pharma.

The company emphasizes a management team with experience across the full drug development spectrum — preclinical and translational research, clinical development, manufacturing, business development and commercialization — combined with a balanced pipeline of ADCs, multispecific antibodies, immunotherapies and precision medicines, and an in-house translational medicine research center built to international standards.

Technology

The pipeline is built on biologics and precision medicine modalities: antibody-drug conjugates (including the EGFR/HER3 bispecific ADC CS5007 and the SSTR2-targeted ADC CS5005), multispecific antibodies (including the PD-1/VEGF/CTLA-4 trispecific CS2009), immunotherapies such as the anti-PD-L1 monoclonal antibody CS1001/sugemalimab and the anti-PD-1 antibody CS1003, and precision medicines. A translational medicine research center in Suzhou supports biomarker and clinical development work, and the company has published quantitative pharmacology research on sugemalimab recognized by EU/UK regulatory agencies.

Go-to-market

CStone commercializes approved products in China and uses regional distributors and international partners to reach markets outside China, including an exclusive commercialization agreement with Arrotex Pharmaceuticals (DBG Health) for Australia and New Zealand. It also works with service partners such as Veristat on regulatory navigation outside its domestic market, and presents clinical and preclinical data at scientific congresses including AACR and ESMO.

Patients with cancer and, more recently, immunology and inflammation indications, in China and globally; commercially the company serves prescribers and healthcare systems via its own products and partner-led distribution, and multinational pharmaceutical and biotech firms via business development deals.

Geography

The company is headquartered in Suzhou, China, with a Suzhou office in Suzhou Industrial Park and a Shanghai office in Pudong New Area. LeadIQ lists its location as Shanghai, China and reports employees across three continents (Asia, North America and Europe). Commercial reach extends to Australia and New Zealand through a partner agreement.

History

CStone was established in late 2015 (sources also describe it as founded in 2016) in Shanghai and Suzhou, and closed a $150 million Series A round in July 2016 backed by Oriza Seed Venture Capital, Boyu Capital and WuXi Healthcare Ventures. It set up the Suzhou Translational Medicine Research Center at the end of 2017 and completed a $260 million Series B in May 2018 led by GIC, bringing cumulative capital raised to $410 million at that time. The company subsequently listed on the Hong Kong Stock Exchange under ticker 2616 and, by 2026, had commercialized products and an expanded ADC and multispecific antibody pipeline. LeadIQ reports total funding of $607 million as of July 2026, with a most recent round of $60 million on April 22, 2026.

Risks & controversies

No controversies are described in the available sources. A third-party source notes that clinical updates for CS2009 were flagged as potentially price-sensitive developments for the listed company.